Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1383260.RA5uwOW1GJQ-WfjEz6tZyphn2o7-ni3F_rfPFJnq5T-tg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1383260.RA5uwOW1GJQ-WfjEz6tZyphn2o7-ni3F_rfPFJnq5T-tg130_assertion type Assertion NP1383260.RA5uwOW1GJQ-WfjEz6tZyphn2o7-ni3F_rfPFJnq5T-tg130_head.
- NP1383260.RA5uwOW1GJQ-WfjEz6tZyphn2o7-ni3F_rfPFJnq5T-tg130_assertion description "[Among the DCCT subjects, 53% were in the intensive treatment group and 47% were in the conventional group; 44% were from the primary prevention cohort (no retinopathy or microalbuminuria at the DCCT baseline) and 56% were from the secondary intervention cohort (mild-to-moderate nonproliferative retinopathy and <200 mg/24 h albumin excretion rate [AER] at baseline).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1383260.RA5uwOW1GJQ-WfjEz6tZyphn2o7-ni3F_rfPFJnq5T-tg130_provenance.
- NP1383260.RA5uwOW1GJQ-WfjEz6tZyphn2o7-ni3F_rfPFJnq5T-tg130_assertion evidence source_evidence_literature NP1383260.RA5uwOW1GJQ-WfjEz6tZyphn2o7-ni3F_rfPFJnq5T-tg130_provenance.
- NP1383260.RA5uwOW1GJQ-WfjEz6tZyphn2o7-ni3F_rfPFJnq5T-tg130_assertion SIO_000772 9356033 NP1383260.RA5uwOW1GJQ-WfjEz6tZyphn2o7-ni3F_rfPFJnq5T-tg130_provenance.
- NP1383260.RA5uwOW1GJQ-WfjEz6tZyphn2o7-ni3F_rfPFJnq5T-tg130_assertion wasDerivedFrom befree-2016 NP1383260.RA5uwOW1GJQ-WfjEz6tZyphn2o7-ni3F_rfPFJnq5T-tg130_provenance.
- NP1383260.RA5uwOW1GJQ-WfjEz6tZyphn2o7-ni3F_rfPFJnq5T-tg130_assertion wasGeneratedBy ECO_0000203 NP1383260.RA5uwOW1GJQ-WfjEz6tZyphn2o7-ni3F_rfPFJnq5T-tg130_provenance.